Creative Biolabs Expands Antibody Portfolio for HIV and HTLV Research
|
Creative Biolabs has expanded its specialized antibody
portfolio targeting structural and envelope proteins from HIV-1, HIV-2,
and HTLV-1. |
New once-weekly HIV pill matches daily treatment in phase 3 trial
Living with HIV often means taking antiretroviral treatment every day to keep the virus under control. While modern HIV medicines have made it ... View article...